Clinical Trial

A Study of LY4064809 in Healthy Adult Chinese Participants

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to measure how much LY4064809 gets into the bloodstream and how long it takes the body to eliminate it in healthy participants. It also looks at safety and tolerability in healthy participants. The study drug will be administered orally. The study will last approximately 21 days, excluding screening.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-11-18; most recent amendment 2026-01-15.
Status change: Active, Not Recruiting → Completed 2026-01-15
Status change: Recruiting → Active, Not Recruiting 2025-12-16
Trial Details
NCT Number NCT07247357
Lead Sponsor Eli Lilly and Company
Collaborators: Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company
Conditions Healthy
Enrollment 10 participants
Start Date 2025-10-24
Primary Completion 2025-12-16 (estimated)
Study Completion 2025-12-16 (estimated)
Updated on ClinicalTrials.gov 2026-01-16